Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Research Paper | Synapse

June 6, 2024Open Access

Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

Key Points

Key points are not available for this paper at this time.

Abstract

Acute graft-versus-host disease (aGVHD) of the lower gastrointestinal (GI) tract is a major cause of morbidity and mortality in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab is a gut-selective anti-α

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Chen et al. (Thu,) studied this question.

synapsesocial.com/papers/68e65d00b6db6435875eaf87 https://doi.org/https://doi.org/10.1038/s41591-024-03016-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease2003 · 147 citations
2Increasing the sample size when the unblinded interim result is promising2004 · 205 citations
3Toxicity and response criteria of the Eastern Cooperative Oncology Group1982 · 11,602 citations
4Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD2012 · 29 citations
5Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation2009 · 54 citations